Luca Gattinoni

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8253292/luca-gattinoni-publications-by-year.pdf
Version: 2024-04-26

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110	15,750	58	115
papers	citations	h-index	g-index
115	18,446	13.5	6.1
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
110	Cancer cells hijack T-cell mitochondria. *Nature Nanotechnology*, **2021**,	28.7	1
109	The New Old CD8+ T Cells in the Immune Paradox of Pregnancy. *Frontiers in Immunology*, **2021**, 12, 765780	3.4	1
108	BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8 T cells. *Nature Immunology*, **2021**, 22, 370-380	19.1	23
107	An engineered IL-2 partial agonist promotes CD8 T cell stemness. *Nature*, **2021**, 597, 544-548	50.4	14
106	Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 T cell stemness and antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6047-6055	11.5	57
105	International Regensburg Center for Interventional Immunology (RCI) symposium on "Synthetic immunology and environment-adapted redirection of T cells", 17-18 July, 2019, Regensburg, Germany. *Cancer Immunology, Immunotherapy*, **2020**, 69, 677-682	7.4	
104	Two subsets of stem-like CD8 memory T cell progenitors with distinct fate commitments in humans. *Nature Immunology*, **2020**, 21, 1552-1562	19.1	57
103	Single-cell RNA-seq reveals TOX as a key regulator of CD8 T cell persistence in chronic infection. *Nature Immunology*, **2019**, 20, 890-901	19.1	198
102	miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8 T cell fate. *Nature Communications*, **2019**, 10, 2157	17.4	36
101	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. *Journal of Clinical Investigation*, **2019**, 129, 1551-1565	15.9	69
100	The transcription factor c-Myb regulates CD8 T cell stemness and antitumor immunity. *Nature Immunology*, **2019**, 20, 337-349	19.1	57
99	CXCR3 Identifies Human Naive CD8 T Cells with Enhanced Effector Differentiation Potential. *Journal of Immunology*, **2019**, 203, 3179-3189	5.3	21
98	AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8 T cells for adoptive immunotherapy. *OncoImmunology*, **2018**, 7, e1488565	7.2	23
97	Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity. *JCI Insight*, **2018**, 3,	9.9	49
96	ONC201 kills breast cancer cells by targeting mitochondria. *Oncotarget*, **2018**, 9, 18454-18479	3.3	45
95	T memory stem cells in health and disease. *Nature Medicine*, **2017**, 23, 18-27	50.5	234
94	Ezh2 phosphorylation state determines its capacity to maintain CD8 T memory precursors for antitumor immunity. *Nature Communications*, **2017**, 8, 2125	17.4	53

93	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. *JCI Insight*, **2017**, 2,	9.9	94
92	Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. *JCI Insight*, **2017**, 2, e90772	9.9	36
91	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. *Cell*, **2016**, 166, 1117-1131.e14	56.2	151
90	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. *Cell Metabolism*, **2016**, 23, 63-76	24.6	210
89	T memory stem cell formation: Caveat mTOR. *EBioMedicine*, **2016**, 4, 3-4	8.8	
88	Enhancing adoptive T cell immunotherapy with microRNA therapeutics. *Seminars in Immunology*, **2016**, 28, 45-53	10.7	23
87	Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. *Journal of Clinical Investigation*, **2016**, 126, 318-34	15.9	152
86	The transcription factor BACH2 promotes tumor immunosuppression. *Journal of Clinical Investigation*, **2016**, 126, 599-604	15.9	39
85	The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. *Science Immunology*, **2016**, 1,	28	233
84	BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. *Nature Immunology*, **2016**, 17, 851-860	19.1	136
83	Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. *Cellular and Molecular Immunology*, **2016**, 13, 502-13	15.4	70
82	Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. *Blood*, **2016**, 128, 519-28	2.2	187
81	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. *Journal of Experimental Medicine*, **2015**, 212, 2095-113	16.6	85
80	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. *Journal of Experimental Medicine*, **2015**, 212, 2027-39	16.6	108
79	miR-155 releases the brakes on antitumor T cells. *OncoImmunology*, **2015**, 4, e1026533	7.2	3
78	TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection. *Cell Reports*, **2015**, 12, 2099-110	16.6	97
77	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. *Cellular and Molecular Immunology*, **2015**,	15.4	7
76	Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. *Vaccine*, **2015**, 33, 914-23	4.1	25

75	Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. *Cancer Immunology Research*, **2015**, 3, 37-47	12.5	22
74	The dark side of T memory stem cells. *Blood*, **2015**, 125, 3519-20	2.2	6
73	miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic □ cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 476-81	11.5	80
72	Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer Research*, **2015**, 75, 296-305	10.1	212
71	Harnessing Stem Cell-Like Memory T Cells for Adoptive Cell Transfer Therapy of Cancer. *Cancer Drug Discovery and Development*, **2015**, 183-209	0.3	1
70	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. *Journal of Cell Biology*, **2015**, 211, 2113OIA259	7.3	
69	Memory T cells officially join the stem cell club. *Immunity*, **2014**, 41, 7-9	32.3	18
68	A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Human Gene Therapy*, **2014**, 25, 1003-12	4.8	113
67	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. *Blood*, **2014**, 124, 3490-500	2.2	87
66	Identification of the genomic insertion site of Pmel-1 TCR □and □transgenes by next-generation sequencing. *PLoS ONE*, **2014**, 9, e96650	3.7	17
65	The short and sweet of T-cell therapy: Restraining glycolysis enhances the formation of immunological memory and antitumor immune responses. *OncoImmunology*, **2014**, 3, e27573	7.2	4
64	Transcriptional regulation of effector and memory CD8+ T cell fates. *Current Opinion in Immunology* , **2013**, 25, 321-8	7.8	26
63	Lineage relationship of effector and memory T cells. *Current Opinion in Immunology*, **2013**, 25, 556-63	7.8	139
62	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. *Cancer Immunology, Immunotherapy*, **2013**, 62, 727-36	7.4	71
61	MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. *Immunity* , **2013**, 38, 742-53	32.3	204
60	BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. *Nature*, **2013**, 498, 506-10	50.4	264
59	Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. *Nature Protocols*, **2013**, 8, 33-42	18.8	138
58	Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. *Journal of Experimental Medicine*, **2013**, 210, 1961-76	16.6	93

57	Moving T memory stem cells to the clinic. *Blood*, **2013**, 121, 567-8	2.2	48
56	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *Journal of Clinical Investigation*, **2013**, 123, 4479-88	15.9	535
55	Superior T memory stem cell persistence supports long-lived T cell memory. *Journal of Clinical Investigation*, **2013**, 123, 594-9	15.9	216
54	Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells. *Blood*, **2013**, 122, 3269-3269	2.2	
53	Stubborn Tregs limit T-cell therapy. *Blood*, **2012**, 120, 2352-4	2.2	2
52	Paths to stemness: building the ultimate antitumour T cell. *Nature Reviews Cancer*, **2012**, 12, 671-84	31.3	376
51	141 The Role of T Memory Stem Cells. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2012**, 59, 59	3.1	1
50	Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. *Journal of Immunotherapy*, **2012**, 35, 651-60	5	195
49	A human memory T cell subset with stem cell-like properties. *Nature Medicine*, **2011**, 17, 1290-7	50.5	1153
48	Th17 cells are long lived and retain a stem cell-like molecular signature. *Immunity*, **2011**, 35, 972-85	32.3	316
47	Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. *Journal of Immunotherapy*, **2011**, 34, 343-52	5	65
46	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. *Blood*, **2011**, 117, 808-14	2.2	226
45	In□vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in□vivo antigen-experienced cells. *Cancer Immunology, Immunotherapy*, **2011**, 60, 739-49	7.4	40
44	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. *Nature Immunology*, **2011**, 12, 1230-7	19.1	136
43	Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. *Genome Research*, **2011**, 21, 1650-8	9.7	138
42	Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. *Clinical Cancer Research*, **2011**, 17, 5343-52	12.9	204
41	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. *Nature Medicine*, **2010**, 16, 339-45	50.5	102
40	Reply to: □catenin does not regulate memory T cell phenotype□*Nature Medicine*, **2010**, 16, 514-515	50.5	15

39	Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. *Clinical Cancer Research*, **2010**, 16, 4695-701	12.9	123
38	Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. *Cancer Research*, **2010**, 70, 6725-34	10.1	187
37	Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. *Journal of Immunotherapy*, **2010**, 33, 1-7	5	197
36	Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 17469-74	11.5	302
35	Pharmacologic induction of CD8+ T cell memory: better living through chemistry. *Science Translational Medicine*, **2009**, 1, 11ps12	17.5	52
34	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. *Nature Medicine*, **2009**, 15, 808-13	50.5	675
33	Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. *Blood*, **2009**, 114, 1776-83	2.2	26
32	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. *Blood*, **2008**, 112, 4746-54	2.2	32
31	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. *Blood*, **2008**, 111, 5326-33	2.2	320
30	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8061-6	11.5	105
29	Tumor-specific Th17-polarized cells eradicate large established melanoma. *Blood*, **2008**, 112, 362-73	2.2	615
28	T-cell receptor gene therapy of established tumors in a murine melanoma model. *Journal of Immunotherapy*, **2008**, 31, 1-6	5	54
27	Treatment of Large Established Murine Melanoma with Th17 Polarized CD4+ T Helper Cells Genetically Engineered to Express MHC Class IIRestricted T Cell Receptor. *Blood*, **2008**, 112, 3911-3911	2.2	
26	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *Journal of Clinical Investigation*, **2007**, 117, 2197-204	15.9	365
25	CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1065-76	7.4	6
24	Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. *Cancer Research*, **2007**, 67, 2425-9	10.1	78
23	Toll-like receptors in tumor immunotherapy. *Clinical Cancer Research*, **2007**, 13, 5280-9	12.9	101
22	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. *Journal of Clinical Investigation*, **2007**, 117, 492-501	15.9	155

21	Programming CD8+ T cells for effective immunotherapy. *Current Opinion in Immunology*, **2006**, 18, 363-70	7.8	59
20	High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. *Molecular Therapy*, **2006**, 13, 151-9	11.7	229
19	CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. *Blood*, **2006**, 108, 3818-23	2.2	51
18	CD8+ T-cell memory in tumor immunology and immunotherapy. *Immunological Reviews*, **2006**, 211, 214-24	11.3	369
17	Adoptive immunotherapy for cancer: building on success. *Nature Reviews Immunology*, **2006**, 6, 383-93	36.5	724
16	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. *Blood*, **2006**, 108, 5210-5210	2.2	
15	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. *Journal of Clinical Investigation*, **2005**, 115, 1616-26	15.9	701
14	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. *Journal of Experimental Medicine*, **2005**, 202, 907-12	16.6	809
13	Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. *Journal of Clinical Oncology*, **2005**, 23, 2155-61	2.2	178
12	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9571-6	11.5	692
11	Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. *Oncology Reports*, **2004**, 12, 145	3.5	6
10	Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma. *Journal of Clinical Oncology*, **2004**, 22, 745-6	2.2	4
9	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 1969-74	11.5	441
8	Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. *Journal of Immunology*, **2004**, 173, 7209-16	5.3	100
7	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. *Journal of Leukocyte Biology*, **2004**, 76, 333-7	6.5	42
6	Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. *Oncology Reports*, **2004**, 12, 145-51	3.5	24
5	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? **2003**, 22, 1081		
4	Renal Cancer Treatment: A Review of the Literature. *Tumori*, **2003**, 89, 476-484	1.7	13

3	Renal cancer treatment: a review of the literature. *Tumori*, **2003**, 89, 476-84	1.7	2
2	Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. *Journal of Steroid Biochemistry and Molecular Biology*, **2002**, 80, 411-8	5.1	9
1	Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules. *Tissue Antigens*, **2000**, 56, 19-29		1